GLP-1 analogs and dual incretin agonists to support weight loss.

Pathological obesity is a key risk factor for the development of life-threatening secondary complications. Until recently, bariatric surgery was the only effective method for obesity sufferers to achieve a sustained reduction in body weight and excess fat mass. Fortunately, there has now been a breakthrough in obesity drug treatment – GLP-1 receptor agonists and dual GLP1/GIP agonists have been shown to significantly help reduce obesity and associated health problems.